These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2878068)

  • 1. Pathogenesis of human primary hypertension: a new approach to the identification of causal factors and to therapy.
    Korner PI; Jennings GL; Esler MD
    J Hypertens Suppl; 1986 Oct; 4(3):S149-53. PubMed ID: 2878068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new approach to the identification of pathogenetic factors and to therapy in human primary hypertension.
    Korner PI; Jennings GL; Esler MD; Broughton A
    J Clin Hypertens; 1987 Jun; 3(2):187-96. PubMed ID: 2956375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regression of left heart hypertrophy in arterial hypertension: principles, experimental and clinical findings].
    Klaus D
    Z Kardiol; 1985; 74 Suppl 7():153-69. PubMed ID: 2936016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of cardiac hypertrophy with drug treatment in spontaneously hypertensive rats.
    Ruskoaho H
    Med Biol; 1984; 62(5):263-76. PubMed ID: 6152298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypertension in elderly--an overview.
    Bhattacharyya A; Das P
    J Indian Med Assoc; 1999 Mar; 97(3):96-101. PubMed ID: 10652909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the effectiveness of the long-term treatment of hypertension patients. I. Changes in hemodynamics and myocardial function].
    Erina EV; Charyev KhE
    Ter Arkh; 1984; 56(9):24-30. PubMed ID: 6151257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible regression of left ventricular hypertrophy during antihypertensive treatment with diuretics and/or beta blockers.
    Cherchi A; Sau F; Seguro C
    J Clin Hypertens; 1987 Jun; 3(2):216-25. PubMed ID: 2886561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The value of angiotensin-converting enzyme inhibitors in the treatment of hypertension].
    Klaus D
    Z Kardiol; 1988; 77 Suppl 3():73-88. PubMed ID: 3062960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of captopril (Tensiomin) in patients with hypertension.
    Török E; Bíró V; Wagner M; Kósa E; Podmaniczky M; Cseh K
    Acta Physiol Hung; 1988; 72 Suppl():51-65. PubMed ID: 2908092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of cardiovascular hypertrophy in the development and maintenance of hypertension.
    Korner PI; Bobik A; Jennings GL; Angus JA; Anderson WP
    J Cardiovasc Pharmacol; 1991; 17 Suppl 2():S25-32. PubMed ID: 1715480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antihypertensive therapy on the cardiovascular amplifiers.
    Korner PI; Adams MA; Jennings GL; Bobik A
    Clin Exp Pharmacol Physiol; 1988 Mar; 15(3):191-7. PubMed ID: 2978739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypertension management in general practice in Iceland].
    Jensdóttir JO; Sigurethsson EL; Thornorgeirsson G
    Laeknabladid; 2006 May; 92(5):375-80. PubMed ID: 16741320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.